Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Long-Term Investments (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Long-Term Investments for 5 consecutive years, with $67.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Investments rose 37.69% to $67.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $67.2 million, a 37.69% increase, with the full-year FY2024 number at $80.6 million, up 635.65% from a year prior.
  • Long-Term Investments was $67.2 million for Q3 2025 at 4D Molecular Therapeutics, down from $123.8 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $137.0 million in Q1 2025 to a low of $1.4 million in Q1 2023.
  • A 5-year average of $52.4 million and a median of $48.8 million in 2024 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: plummeted 97.09% in 2023, then soared 4379.86% in 2024.
  • 4D Molecular Therapeutics' Long-Term Investments stood at $67.7 million in 2021, then crashed by 92.75% to $4.9 million in 2022, then soared by 123.19% to $11.0 million in 2023, then skyrocketed by 635.65% to $80.6 million in 2024, then fell by 16.65% to $67.2 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Long-Term Investments are $67.2 million (Q3 2025), $123.8 million (Q2 2025), and $137.0 million (Q1 2025).